

# Saxenda® Dosing Guide

## Initiating treatment with Saxenda® for chronic weight management


Saxenda® (liraglutide) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:<sup>1</sup>

- 30 kg/m<sup>2</sup> or greater (obese), or
- 27 kg/m<sup>2</sup> or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.



Simple, once-daily dosing at any time of day, independent of meals<sup>1</sup>


Patients should follow a progressive dose escalation to achieve the maintenance dose of 3.0 mg/day



- If patients do not tolerate an increased dose during dose escalation, each step in the dose escalation can be delayed up to 7 days
- If a patient has not lost at least 5% of their initial body weight after 12 weeks on the 3.0 mg maintenance dose, treatment with Saxenda® should be discontinued

Demonstrate the first injection in the office to help patients get started

1 attach needle



2 select dose



3 inject dose



4 remove needle



The Saxenda<sup>®</sup> pen is designed to be used with NovoFine<sup>®</sup> Plus—the only 4 mm, universal pen needle with comfort-base technology so patients can experience a **virtually painless injection**.\*

\* Comparative clinical significance has not been established.

## SaxendaCare<sup>®</sup> Patient Support Program

### Encourage your patients to enrol in SaxendaCare<sup>®</sup>

A FREE patient support program to help patients on Saxenda<sup>®</sup> work towards their weight management goals.

#### Patients will receive access to:

- ✓ Resources to get them started with Saxenda<sup>®</sup>
- ✓ A guided program with regular check-ins via email
- ✓ Scientifically-validated behavioural strategies used by weight management experts to help them incorporate the right lifestyle changes

Patients can enrol by visiting [www.SaxendaCare.ca](http://www.SaxendaCare.ca)

Consult the Product Monograph at [http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/Saxenda\\_PM\\_English.pdf](http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/Saxenda_PM_English.pdf) for more information on conditions of clinical use, contraindications, warnings and precautions, adverse reactions, drug interactions, and dosing information. The Product Monograph is also available by calling Novo Nordisk at 1-800-465-4334.

#### Reference:

1. Saxenda<sup>®</sup> Product Monograph, Novo Nordisk Canada Inc., 2017.



Saxenda<sup>®</sup>, SaxendaCare<sup>®</sup> and NovoFine<sup>®</sup> Plus are registered trademarks of Novo Nordisk A/S and used under license by Novo Nordisk Canada Inc.  
**Novo Nordisk Canada Inc.**, Tel: (905) 629-4222 or 1-800-465-4334. [www.novonordisk.ca](http://www.novonordisk.ca)  
© Novo Nordisk Canada Inc. CA20SX00008E

